Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

Sophie V Fletcher; Mark G Jones; Elizabeth A Renzoni; Helen Parfrey; Rachel K Hoyles; Katherine Spinks; Maria Kokosi; Apollinaris Kwok; Chris Warburton; Vanessa Titmuss; Muhunthan Thillai; Nicola Simler; Toby M Maher; Christopher J Brereton; Felix Chua; Athol U Wells; Luca Richeldi; Lisa G Spencer

doi:10.1183/23120541.00049-2018

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

ERJ Open Res. 2018 Oct 19;4(4):00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

Authors

Sophie V Fletcher¹, Mark G Jones¹, Elizabeth A Renzoni², Helen Parfrey³, Rachel K Hoyles⁴, Katherine Spinks⁵, Maria Kokosi², Apollinaris Kwok⁶, Chris Warburton⁶, Vanessa Titmuss⁵, Muhunthan Thillai³, Nicola Simler³, Toby M Maher², Christopher J Brereton¹, Felix Chua², Athol U Wells², Luca Richeldi¹, Lisa G Spencer⁶

Affiliations

¹ NIHR Southampton Respiratory Biomedical Research Centre University Hospital Southampton and Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
² ILD Unit, Royal Brompton Hospital, London, UK.
³ Papworth Hospital, Cambridge, UK.
⁴ John Radcliffe Hospital, Oxford, UK.
⁵ Queen Alexandra Hospital, Portsmouth, UK.
⁶ Aintree University Hospital, Liverpool, UK.

Abstract

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67.

Abstract

Grants and funding